|[February 20, 2014]
Arrowhead to Present at RBC Capital Markets' Global Healthcare Conference
PASADENA, Calif. --(Business Wire)--
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that
President and CEO, Christopher Anzalone, Ph.D., will present at the 2014
RBC Capital Markets' Global Healthcare Conference on Wednesday, February
26, 2014 at 3:30 p.m. EST at the New York Palace Hotel.
A live webcast of the presentation can be accessed by visiting the News
& Events section of the company's website, http://www.arrowheadresearch.com/pesentations.
A replay will also be archived on the website and available for 90 days.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
drug delivery technologies to develop targeted drugs based on the RNA
interference mechanism that efficiently silence disease-causing genes.
Arrowhead technologies also enable partners to create peptide-drug
conjugates that specifically home to cell types of interest while
sparing off-target tissues. Arrowhead's pipeline includes clinical
programs in chronic hepatitis B virus and partner-based programs in
obesity and oncology.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter (News - Alert) @ArrowRes.
To be added to the Company's email list to receive news directly, please
send an email to email@example.com.
[ InfoTech Spotlight's Homepage ]